Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218265 | 0.81 | ROCK1 (0.43) | ROCK1ALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL8212418 | 0.79 | TAAR1 (0.49) | ALDH1A1MAPTNPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8212408 | 0.77 | ROCK1 (0.40) | ROCK1ALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL8215633 | 0.76 | KIF11 (0.50) | MAPTKMT2AMEN1 | |
| SCHEMBL16356393 | 0.75 | ROCK1 (0.40) | ROCK1SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL14494432 | 0.74 | MAPT (0.41) | ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A | |
| SCHEMBL8243200 | 0.74 | MAPT (0.41) | ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A | |
| SCHEMBL8220090 | 0.74 | ROCK1 (0.40) | ROCK1ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8208836 | 0.73 | MEN1 (0.52) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8212593 | 0.71 | SMN1; SMN2 (0.47) | ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ROCK1 3406/4885ALDH1A1 1502/4885MAPT 739/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ROCK1 3702/4885ALDH1A1 1369/4885MAPT 874/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | ROCK1 3037/4885ALDH1A1 1607/4885MAPT 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.